Coya Therapeutics Files 8-K: Officer/Director Changes & Compensation
Ticker: COYA · Form: 8-K · Filed: 2026-04-02T08:48:35-04:00
Sentiment: neutral
Topics: officer-departure, director-election, compensation
TL;DR
Coya Therapeutics filed an 8-K on 4/2/26 detailing leadership changes and compensation. Keep an eye on strategy shifts.
AI Summary
Coya Therapeutics, Inc. filed an 8-K on April 2, 2026, reporting changes in officers and directors, and compensatory arrangements. The filing includes exhibits detailing these changes and financial statements, with the period of report ending March 29, 2026.
Why It Matters
This filing signals potential shifts in Coya Therapeutics' leadership and executive compensation structure, which could impact the company's strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key personnel and compensation arrangements can introduce uncertainty regarding future company strategy and performance.
Key Players & Entities
- Coya Therapeutics, Inc. (company) — Filer of the 8-K report
- 0001835022 (company) — CIK number for Coya Therapeutics, Inc.
- 2026-04-02 (date) — Filing date of the 8-K
- 2026-03-29 (date) — Period of report end date
FAQ
What specific changes were made to Coya Therapeutics' officer or director positions?
The 8-K filing, specifically Item 5.02, details the departure of directors or certain officers, election of directors, and appointment of certain officers.
What type of compensatory arrangements are detailed in this filing?
Item 5.02 of the 8-K filing covers compensatory arrangements of certain officers.
When was this 8-K filing accepted by the SEC?
The filing was accepted on 2026-04-02 at 08:48:35.
What is the CIK number for Coya Therapeutics, Inc.?
The CIK number for Coya Therapeutics, Inc. is 0001835022.
Which exhibits are included with this 8-K filing?
The filing includes exhibits such as EX-10.1 and EX-99.1, along with XBRL data files.
From the Filing
EDGAR Filing Documents for 0001193125-26-139094 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-139094 Filing Date 2026-04-02 Accepted 2026-04-02 08:48:35 Documents 14 Period of Report 2026-03-29 Items Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K d104763d8k.htm iXBRL 8-K 30908 2 EX-10.1 d104763dex101.htm EX-10.1 45898 3 EX-99.1 d104763dex991.htm EX-99.1 14070 7 GRAPHIC g104763g0401212644127.jpg GRAPHIC 7363 Complete submission text file 0001193125-26-139094.txt 240811 Data Files Seq Description Document Type Size 4 XBRL TAXONOMY EXTENSION SCHEMA coya-20260329.xsd EX-101.SCH 2874 5 XBRL TAXONOMY EXTENSION LABEL LINKBASE coya-20260329_lab.xml EX-101.LAB 18734 6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE coya-20260329_pre.xml EX-101.PRE 11722 17 EXTRACTED XBRL INSTANCE DOCUMENT d104763d8k_htm.xml XML 3766 Mailing Address 12645 MEMORIAL DR., SUITE F1 #305 HOUSTON TX 77024 Business Address 12645 MEMORIAL DR., SUITE F1 #305 HOUSTON TX 77024 650.739.3939 Coya Therapeutics, Inc. (Filer) CIK : 0001835022 (see all company filings) EIN. : 000000000 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-41583 | Film No.: 26830788 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)